It is important to note, however, that both Tocilizumab and Siltuximab can alter the measure of circulating IL-6 in patients, and thus, the assessment of recovery from CRS must then rely on clinical judgment of patient’s symptoms rather than laboratory values alone [60]. This evidence concerns the gene IL6 and congenital rubella syndrome.